Trial reportBlood2022
Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer.
Trial report in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03055026 (Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer), which is not on this map. Cited by 29 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer: a Randomized, Double Blind, Placebo-controlled Study.
Who cites it
29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- The efficacy and safety of extended thromboprophylaxis after colorectal surgery: a systematic review and meta-analysis.International journal of colorectal disease · 2025Pooled it
- Advances and Challenges in the Application of Novel Oral Anticoagulants for Venous Thromboembolism Prevention Following Colorectal Cancer Surgery.Journal of gastrointestinal cancer · 2025Pooled it
- The 2024 Korean Enhanced Recovery After Surgery (ERAS) guidelines for colorectal cancer: a secondary publication.Annals of coloproctology · 2025Guideline
- Comparison of efficacy and safety of thrombus prevention strategies after abdominal and pelvic cancer surgery: Bayesian network based meta-analysis.Frontiers in oncology · 2025Pooled it
- SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis.World journal of surgical oncology · 2024Pooled it
- Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Role of extended venous thromboembolism prophylaxis in patients with colorectal neoplasia who underwent minimally invasive colorectal surgery within an enhanced recovery after surgery protocol.Surgical endoscopy · 2026Article
- Post-discharge VTE prophylaxis after bariatric surgery: balancing bleeding risk and thrombosis prevention in 275,843 patients.Surgical endoscopy · 2026Article
- Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges.Journal of thrombosis and thrombolysis · 2026Review
- Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.International journal of molecular sciences · 2026Review
- Role of Post-discharge Venous Thromboembolism Prophylaxis after Colorectal Surgery.Clinics in colon and rectal surgery · 2026Review
- Effectiveness and Safety of Long-Term Venous Thromboembolism Prophylaxis After Colorectal Cancer Surgery: A Retrospective Study.Drugs - real world outcomes · 2025Article
- Ultrasound-guided quadratus lumborum block with general anesthesia for perioperative circulatory stability in colorectal cancer surgery.World journal of gastrointestinal surgery · 2025Article
- Esketamine modulates postoperative biochemical markers of oxidative stress, inflammation, and immune dysregulation in laparoscopic colorectal cancer surgery.Journal of medical biochemistry · 2025Article
- Safety and Efficacy of Direct Oral Anticoagulants Apixaban and Rivaroxaban Versus Standard Therapy for VTE Prophylaxis Post Cancer Surgery-A Network Meta-Analysis of Randomized Clinical Trials.Journal of clinical medicine · 2025Review
- Evaluating Rivaroxaban for Thromboprophylaxis in Cancer Patients with Long-Term Venous Access Devices: A Retrospective Cohort Study.Vascular health and risk management · 2025Article
- Article
- The clinical effect of endoscopic and open surgery in the treatment of thyroid cancer and their effect on the blood coagulation state: a comparative study.Annals of surgical treatment and research · 2024Article
- Effectiveness of magnetic resonance imaging and spiral computed tomography in the staging and treatment prognosis of colorectal cancer.World journal of gastrointestinal surgery · 2024Article
Corrections and comments
- Commented on by
Authors and funding
26 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical benefit of extended prophylaxis for venous thromboembolism (VTE) after laparoscopic surgery for cancer is unclear. The efficacy and safety of direct oral anticoagulants for this indication are unexplored. PROphylaxis of venous thromboembolism after LAParoscopic Surgery for colorectal cancer Study II (PROLAPS II) was a randomized, double-blind, placebo-controlled, investigator-initiated, superiority study aimed at assessing the efficacy and safety of extended prophylaxis with rivaroxaban after laparoscopic surgery for colorectal cancer. Consecutive patients who had laparoscopic surgery for colorectal cancer were randomized to receive rivaroxaban (10 mg once daily) or a placebo to be started at 7 ± 2 days after surgery and given for the subsequent 3 weeks. All patients received antithrombotic prophylaxis with low-molecular-weight heparin from surgery to randomization. The primary study outcome was the composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography-detected deep vein thrombosis (DVT), or VTE-related death at 28 ± 2 days after surgery. The primary safety outcome was major bleeding. Patient recruitment was prematurely closed due to study drug expiry after the inclusion of 582 of the 646 planned patients. A primary study outcome event occurred in 11 of 282 patients in the placebo group compared with 3 of 287 in the rivaroxaban group (3.9 vs 1.0%; odds ratio, 0.26; 95% confidence interval [CI], 0.07-0.94; log-rank P = .032). Major bleeding occurred in none of the patients in the placebo group and 2 patients in the rivaroxaban group (incidence rate 0.7%; 95% CI, 0-1.0). Oral rivaroxaban was more effective than placebo for extended prevention of VTE after laparoscopic surgery for colorectal cancer without an increase in major bleeding. This trial was registered at www.clinicaltrials.gov as #NCT03055026.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.